Cumberland Pharmaceuticals to submit rolling NDA for ifetroban in Duchenne cardiomyopathy
Cumberland Pharmaceuticals announced plans to file a New Drug Application for ifetroban, a once‑daily oral thromboxane‑receptor blocker, as a treatment for cardiomyopathy in Duchenne muscular dystrophy. The FDA granted a rolling review after a pre‑NDA meeting, but raised concerns about the adequacy of efficacy evidence and requested additional analyses. The pivotal FIGHT DMD Phase 2 trial showed a 5.4% absolute improvement in left‑ventricular ejection fraction (p = 0.002) and the safety database includes more than 1,400 subjects across about 30 studies. The drug holds Orphan, Rare Pediatric Disease and Fast‑Track designations.
Why it matters
The rolling review allows the company to submit completed sections of the NDA ahead of the full filing, potentially accelerating the review timeline, but the FDA’s request for further analysis may delay approval if the additional data are not satisfactory. The outcome will determine whether Cumberland can bring the first approved therapy for DMD‑related heart disease to market, impacting future revenue streams.
Key facts
- 1The FDA granted Cumberland a rolling review of the NDA, permitting staged submission of application sections. prnewswire.com
- 2The 12‑month FIGHT DMD trial demonstrated a 5.4% absolute improvement in left ventricular ejection fraction (p = 0.002) versus a control group. prnewswire.com
- 3Ifetroban has received Orphan Drug, Rare Pediatric Disease and Fast Track designations from the FDA. investing.com
- 4The safety database includes more than 1,400 subjects across approximately 30 clinical studies. investing.com
- 5Cumberland plans to use data from the FIGHT DMD trial combined with two natural‑history databases as the pivotal evidence in the NDA. prnewswire.com
- 6The company expects its balance sheet, bolstered by a recent $100 million transaction, to fund the NDA submission without needing dilutive financing. finance.yahoo.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.